Humanin

Background

Humanin is a small mitochondrial-derived peptide (MDP) originally identified as a neuroprotective factor in screens for molecules rescuing neuronal cells from Alzheimer’s disease–related insults.[12][13] It is a 24–amino acid peptide in humans (some species encode a 21–amino acid variant) translated from an open reading frame within the mitochondrial 16S rRNA gene (MT-RNR2).[12][13][15] Humanin is also referred to as MT-RNR2-derived peptide, and multiple synthetic analogues have been developed, including HNG (S14G-humanin; glycine substitution at position 14) and HNGF6A, which display enhanced potency.[4][12][13]

Humanin is widely conserved across species and is detectable in multiple tissues and in circulation, suggesting both autocrine/paracrine and endocrine functions.[12][15] Circulating levels generally decline with age in humans and several animal models, consistent with proposed roles in aging and age-associated diseases.[15]

Since its discovery in the early 2000s, humanin has been implicated in stress resistance, neuroprotection, cardiometabolic regulation, and modulation of lifespan and healthspan in preclinical models.[12][13][15] At present, humanin and its analogues remain investigational research agents without marketing authorization as medicinal products in the US or EU.

Mechanism of action

Humanin exerts cytoprotective and anti-apoptotic effects through both intracellular actions and binding to cell-surface receptors.

Receptor interactions

• Humanin binds a trimeric receptor complex composed of WSX-1 (IL-27Rα), CNTFR, and gp130, activating JAK–STAT and ERK signaling pathways that promote cell survival.[12][13]
• It also interacts with formyl peptide receptor-like 1 (FPRL1/FPR2), a G protein–coupled receptor, modulating intracellular calcium and survival pathways in certain cell types.[12][13]

Intracellular targets

• Humanin binds pro-apoptotic BCL-2 family proteins such as BAX, tBID, and BimEL, inhibiting their translocation to mitochondria and thereby suppressing cytochrome c release and caspase activation.[12][13]
• Humanin interacts with IGFBP-3 and may modulate IGF-1 signaling and apoptosis in some contexts.[11][12]

Functional consequences

Across cell and animal models, humanin demonstrates:

• Anti-apoptotic and cytoprotective activity in response to oxidative stress, serum starvation, hypoxia, endoplasmic reticulum stress, and toxic protein aggregates.[12][13]
• Neuroprotective effects, including protection against amyloid-β toxicity, excitotoxicity, and mitochondrial toxins.[12][13][14]
• Mitochondrial support, with reported improvement in mitochondrial membrane potential, respiratory function, and mitophagy in neurodegenerative models.[12][14]
• Autophagy modulation, particularly with the HNG analogue, where humanin is reported to induce protective autophagy and mitigate metabolic and oxidative stress in various in vitro and in vivo models.[4]
• Metabolic signaling, including effects on insulin sensitivity, lipid metabolism, and inflammatory markers, suggesting a role in cardiometabolic homeostasis.[4][12][15]

Evidence summary

Neurodegenerative and neurological disease models

• Alzheimer’s disease (AD) models: Initial discovery studies demonstrated that humanin protects neuronal cells from death induced by AD-related insults such as amyloid-β and mutant APP/tau in vitro.[12][13] In transgenic AD mouse models, intracerebroventricular or systemic administration of humanin or HNG reduced neuronal loss and improved behavioral readouts in small cohorts (typical group sizes 8–15 mice), although protocols and sample sizes vary across studies.[12][13]

• Parkinson’s disease (PD): In a 2023 preclinical study, intranasal humanin was evaluated in PD patients and mouse models.[14]

  • Plasma humanin levels were measured in PD patients and healthy controls (cross-sectional cohort; sample size not large and not powered for clinical outcomes) and in transgenic or neurotoxic mouse models, where PD was associated with altered circulating humanin.[14]
  • In MPTP and α-synuclein mouse models, intranasal humanin improved mitochondrial function, reduced dopaminergic neuron loss, and attenuated behavioral deficits; treated groups typically included 8–12 animals.[14]

• Chemotherapy-induced toxicity: A commentary reviewing work by Eriksson et al. reported that an HNG analogue almost completely prevented bortezomib-induced growth plate toxicity and growth failure in mice without reducing antitumor efficacy.[11] Group sizes in the original experiments were on the order of 8–10 animals per arm.[11]

• General neuroprotection: A 2024 review summarized extensive in vitro and animal data indicating that humanin and analogues protect neurons from diverse insults (Aβ, oxidative stress, ischemia, excitotoxicity) and improve functional outcomes in stroke and neurodegenerative models.[13]

Metabolic and aging-related studies

• Lifespan and healthspan: A 2020 study by Lee et al. evaluated humanin and HNG in multiple species.[15]

  • Circulating humanin levels declined with age in humans and several mammals, but remained relatively stable in the long-lived naked mole-rat.[15]
  • Twice-weekly treatment of aged mice with HNG improved metabolic health parameters (glucose tolerance, insulin sensitivity) and reduced inflammatory markers; survival analyses suggested effects on healthspan, though evidence for lifespan extension was model-dependent.[15] Mouse cohorts typically numbered 15–25 animals per group.[15]

• Autophagy and metabolic disorders: A 2023 review highlighted that humanin and particularly HNG act as autophagy inducers, improving cell survival under metabolic and oxidative stress in models of diabetes, obesity, and nonalcoholic fatty liver disease.[4] Most data derive from rodent and cell studies; robust human intervention data are lacking.[4]

Human observational and early translational data

• Circulating levels and disease associations: Human observational studies (summarized in reviews) report associations between circulating humanin and aging, frailty, cognitive status, and metabolic disease, but sample sizes are modest and designs largely cross-sectional.[12][15] For example, one study cited in Lee et al. found that levels in offspring of centenarians were higher than in age-matched controls (sample sizes on the order of dozens per group).[15]

• Clinical trials: As of mid-2026, no completed phase 2 or phase 3 interventional trials of humanin or its analogues in humans are indexed in major registries or reported in peer-reviewed literature. Available human data are largely observational or exploratory biomarker studies.[12][13][15]

Overall, the evidence base is dominated by preclinical in vitro and animal studies, with limited early translational work in humans and no established clinical efficacy.

Clinical and research uses

Investigational and preclinical applications

Humanin and its analogues are being investigated preclinically in several domains:

• Neurodegenerative diseases (Alzheimer’s, Parkinson’s, other dementias) for neuroprotection and mitochondrial support.[12][13][14]
• Chemotherapy-induced toxicity, particularly growth plate toxicity in pediatric-relevant models and possibly neuropathy or cardiotoxicity.[11][12]
• Metabolic syndrome and diabetes, focusing on insulin resistance, β-cell survival, hepatic steatosis, and autophagy modulation.[4][12]
• Cardiovascular disease and ischemia-reperfusion injury, leveraging anti-apoptotic and anti-oxidative effects in cardiomyocytes and vascular cells.[12]
• Aging and geroscience, with HNG evaluated as a candidate geroprotective agent based on effects on healthspan and inflammatory markers in mice.[15]

Off-label or non-regulated use

There is no authoritative documentation of regulated clinical use of humanin as a drug. Any use of synthetic humanin or analogues in humans currently occurs in experimental or non-regulated settings and should be considered research-only and off-label.

Dosing context

No standardized therapeutic dosing has been established. Reported regimens derive from animal studies and are not directly translatable to human clinical practice.

• In aging and metabolic studies, HNG has been administered to mice twice weekly by intraperitoneal injection at doses commonly around 5 mg/kg (range varies across studies) over several months, leading to improved metabolic parameters and inflammatory profiles.[15]
• In neurodegenerative models, humanin or HNG has been delivered via intracerebroventricular, intranasal, intravenous, or intraperitoneal routes, with doses typically in the 0.1–5 mg/kg range in rodents, depending on route and model.[12][14]
• In PD mouse models, intranasal humanin was administered repeatedly over days to weeks, at doses selected to achieve central nervous system exposure without overt toxicity in small cohorts.[14]

These regimens are experimental, optimized for specific animal models, and cannot be assumed safe or effective in humans. No approved human dosing schedule exists.

Safety profile

Preclinical safety observations

Across diverse cell and animal models, humanin and its analogues have generally shown favorable tolerability at experimentally used doses:

• In mice receiving chronic HNG treatment for aging and metabolic studies, no major adverse clinical signs, weight loss, or organ toxicity were reported at the doses used, though detailed GLP toxicology was not performed.[15]
• In PD mouse models, repeated intranasal humanin improved neurobehavioral outcomes without apparent neurotoxicity or systemic adverse effects in standard observations.[14]
• In chemotherapy co-treatment models, humanin analogues mitigated growth plate toxicity without attenuating the anticancer effect of bortezomib in mice.[11]

However, there are important limitations:

• Systematic toxicology data (e.g., dose-ranging, reproductive toxicity, genotoxicity) are not available in the published literature.[12][13][15]
• Long-term effects of chronic exposure, especially at higher doses or in combination with other drugs, remain unclear.[12][13]

Potential risks and theoretical concerns

Based on mechanism and preclinical data, potential concerns include:

• Interference with apoptosis: As an anti-apoptotic agent, humanin could theoretically protect not only normal cells but also malignant or premalignant cells, potentially affecting tumor surveillance.[12][13] Some studies suggest it does not blunt chemotherapeutic efficacy in specific models, but overall oncologic risk is insufficiently characterized.[11]
• Metabolic modulation: Effects on insulin and IGF signaling, as well as autophagy, could have complex consequences in individuals with diabetes, obesity, or cancer.[4][12]
• Immunogenicity: Being a peptide, repeated administration could elicit immune responses, especially for non-native analogues, although systematic data are lacking.[12][13]

Contraindications and interactions

No formal contraindications or drug–drug interaction profiles have been established, as humanin is not an approved medicinal product. Potential areas of caution, based on mechanism and preclinical context, include:

• Active malignancy or high cancer risk, given anti-apoptotic actions and incomplete oncologic safety data.[12][13]
• Concurrent chemotherapy, where theoretical interactions could be beneficial (protecting normal tissue) or harmful (protecting tumor cells), and current evidence is limited to specific preclinical models.[11]
• Severe metabolic or endocrine disorders, where modulation of IGF/insulin pathways and autophagy may have unpredictable effects.[4][12]

Comprehensive human safety data are not available.

Regulatory status

• United States (FDA): Humanin and its analogues are not approved as drugs, biologics, or dietary ingredients by the US Food and Drug Administration. They are used only in preclinical and exploratory translational research.[12][13][15]
• European Union (EMA and national agencies): There are no EMA-authorized medicinal products containing humanin or its analogues. Published literature and regulatory databases do not indicate ongoing advanced clinical development programs for humanin-based therapeutics.[12][13]

As of the latest available data, humanin remains an experimental mitochondrial-derived peptide under investigation in academic and preclinical industry settings, with no marketing authorization for therapeutic use in either the US or EU.